Search

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: To explore the expression and clinical significance of BMP - 7 in preeclampsia kidney damage. Methods: 98 cases of patients with preeclampsia kidney damage from obstetrics and gynecology department from March 2012 to December 2013 were selected as the research object, and another 30 cases of healthy pregnant women was considered as controls. The concentration of serum and urine BMP - 7 protein and beta 2 microglobulin (β2-MG) in urine was detected by ELISA, 24 h urine protein quantitative determination was performed with benzyl cable chloramine turbidimetry. Results: ① Compared with control group, the concentration of urine and serumBMP 7 protein in the preeclampsia group was decreased significantly (P < 0.05); ②With the progression of disease, the concentration of urine and serum BMP 7 protein, the quantity of urine albumin of β2-MG was significantly increased in preeclampsia group (P < 0.05);③the concentration of urine and serumBMP 7 protein in preeclampsia group was respectively positively correlated with quantity of urinary albumin and β2-MG (P < 0.05). Conclusions: The serum BMP 7 protein is significantly reduced in the patients with preeclampsia renal damage, which can be used to evaluate the progress of preeclampsia renal damage, and provide guidance for clinic. [ABSTRACT FROM AUTHOR]

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Allogeneic hematopoietic stem cell transplantation has become one of the effective means of treatment of certain malignancies. But with its of graft versus host disease(GVHD) is one of the important complications of death patients after transplantation.Therefore, how to induce GVHD after transplantation immune tolerance to control, especially control the occurrence of acute graft versus host disease(a GVHD) has become an important part of the study. The occurrence of GVHD mechanism is very complicated. But ultimately identify for mature T cells within the bone marrow donor recipient cells on the surface of the MHC- I and MHC II and caused peptides presented by donor T cell activation, proliferation and infiltration of GVHD target organs such as skin, small intestine and the liver and lead to target organs damage. Clinical implantology and transplantation immunology is one of the contents of the main crack how to control the occurrence of GVHD development. The prevention and treatment is the key to success of allogeneic hematopoietic stem cell transplantation. Individual transplantation is one of the main factors of long-term survival. Related cytokines application and related mechanism research, to a great extent, effective control of the development of GVHD. such as CD4+CD25+Tregs, ecto-59-nucleotidase(CD73), natural killer cell(NK cells), Granulocyte colony-stimulating-factor(G-CSF), Mesenchymal stem cells(MSC), Inducible T cell costimnlator(ICOS) and so on.This article about the cause of GVHD phenomenon and summarize the latest progress. [ABSTRACT FROM AUTHOR]

Gastric cancer is one of the common malignant tumors. It has a higher morbidity than other tumors and its death toll accounts for a quarter. There are nearly 400,000 newly increased patients per year, but the early diagnostic rate is lower than 20%. So gastric cancer has become one of the most serious diseases that endanger our healthy. Interleukins, as the interaction lymphatic factors between white blood cells and immune cells, play an important role in mediating the activation, proliferation and differentiation of the T and B cells, as well as the inflammatory response. In recent years, more and more scholars found that, they have an intimate contact with the occurrence and development of tumor. So far, 29 kinds of interleukins have been discovered and have been named IL-1～IL-29, they bear the corresponding mission respectively. A large number of experiments and literature at home and abroad showed that interleukin-1, 6, 8 have a close relationship with the gastric cancer. It puts forward a new idea for the early diagnosis and treatment, and then improve the early diagnostic rate and treatment of gastric cancer. In this paper, the sources, molecular structure and receptor of IL-1, IL-6, IL-8 are summarized briefly, and the biological characteristics and the relation with gastric cancer are also described. [ABSTRACT FROM AUTHOR]